

1645


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

15120

In Re Application Of: Joachim Hauber, et al.

Serial No.  
10/025,367Filing Date  
December 19, 2001Examiner  
UnassignedGroup Art Unit  
1645

Title:

**COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS**

Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
  2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

**RECEIVED**

MAY 01 2003

TECH CENTER 1600/2900

Also submitted herewith is:

- a certification as specified in 37 CFR 1.97(e);


**OR**

- the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
 15120

In Re Application Of: Joachim Hauber, et al.



Serial No.  
 10/025,367

Filing Date  
 December 19, 2001

Examiner  
 Unassigned

Group Art Unit  
 1645

Title:

**COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \_\_\_\_\_ is attached.
- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
  - Charge the amount of \_\_\_\_\_
  - Credit any overpayment.
  - Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_ (Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on April 24, 2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Michelle Mustafa

Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

*Peter I. Bernstein*  
 Signature

Peter I. Bernstein  
 Registration No. 43,497  
**SCULLY, SCOTT, MURPHY & PRESSER**  
 400 Garden City Plaza  
 Garden City, NY 11530  
 (516) 742-4343

**RECEIVED**

Dated: April 24, 2003

MAY 01 2003

TECH CENTER 1600/2900

PIB:dg

CC:



IDS/ #9  
J 5.2.03

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant(s):** Joachim Hauber, et al.

**Examiner:** Unassigned

**Serial No:** 10/025,367

**Art Unit:** 1645

**Filed:** December 19, 2001

**Docket:** 15120

**For:** COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS

**Dated:** April 24, 2003

Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. International Patent Publication No. WO 95/21916, dated August 17, 1995;
2. Rebel J.M.J. et al., "Identification of a pp32-Related Locus on Chromosome 12", *EMBL Genbank #HSU71084* (1997), XP002106402;
3. Ross R.A. et al., "HuD, a Neuronal-Specific RNA-Binding Protein, is a Potential Regulator of *MYCN* Expression in Human Neuroblastoma Cells", *European Journal of Cancer* 33(12): 2071-2074 (1997);

---

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on April 24, 2003.

Dated: April 24, 2003


  
Michelle Mustafa

4. Chung S. et al., "The Elav-like Proteins Bind to a Conserved Regulatory Element in the 3'-Untranslated Region of GAP-43 mRNA\*", *The Journal of Biological Chemistry* 272(10):6593-6598 (1997), XP002920798;
5. International Patent Publication No. WO 99/12965, dated March 18, 1999; and
6. Brennan C.M. et al., "Protein Ligands to HuR Modulate Its Interaction with Target mRNAs In Vivo", *The Journal of Cell Biology* 151(1):1-13 (2000), XP002230286.

The references were cited in a Search Report received from the European Patent Office, dated February 27, 2003. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Peter I. Bernstein  
Registration No.: 43,497

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

PIB:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional)	Application Number
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>		15120	10/025,367
(Use several sheets if necessary)			
		Applicant(s) Joachim Hauber, et al.	
		Filing Date December 19, 2001	Group Art Unit 1645

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 95/21916	8/17/95	PCT			<b>RECEIVED</b>	
		WO 99/12965	3/18/99	PCT			MAY 01 2003	
							TECH CENTER 1600/2900	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Rebel J.M.J. et al., "Identification of a pp32-Related Locus on Chromosome 12", <i>EMBL Genbank #HSU71084</i> (1997), XP002106402
	Ross R.A. et al., "HuD, a Neuronal-Specific RNA-Binding Protein, is a Potential Regulator of MYCN Expression in Human Neuroblastoma Cells", <i>European Journal of Cancer</i> 33(12): 2071-2074 (1997)
	Chung S. et al., "The Elav-like Proteins Bind to a Conserved Regulatory Element in the 3'-Untranslated Region of GAP-43 mRNA*", <i>The Journal of Biological Chemistry</i> 272(10):6593-6598 (1997), XP002920798
	Brennan C.M. et al., "Protein Ligands to HuR Modulate Its Interaction with Target mRNAs In Vivo", <i>The Journal of Cell Biology</i> 151(1):1-13 (2000), XP002230286

EXAMINER	DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.